Physician profile
Robb V Rydzynski
NPI 1720016306
$6,722.52
in general payments reported to CMS, 2019-2025
34 companies · $138 in 2025
The $138 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,602 · 2020: $376 · 2021: $780 · 2022: $962 · 2023: $498 · 2024: $366 · 2025: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $983 · Education: $19.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $982.88 |
| Education | $19.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $3,440.26 | 2019-2025 | Altis |
| Axonics, INC. | $727.80 | 2020-2024 | Axonics |
| Abbvie INC. | $409.37 | 2019-2024 | Ubrelvy |
| Pfizer INC. | $360.81 | 2020-2025 | |
| Mayne Pharma Commercial LLC | $353.34 | 2021 | |
| Astellas Pharma US INC | $286.86 | 2019-2024 | Veozah |
| Sumitomo Pharma America, INC. | $148.70 | 2023-2024 | Myfembree, Gemtesa |
| Myovant Sciences INC. | $114.00 | 2021-2022 | |
| Therapeuticsmd, INC. | $90.47 | 2020-2021 | |
| Allergan, INC. | $87.42 | 2019-2021 | |
| Novo Nordisk INC | $79.81 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Ethicon US, LLC | $57.62 | 2022 | |
| Organon LLC | $56.44 | 2022-2025 | Nexplanon |
| Boston Scientific Corporation | $56.35 | 2019-2025 | Axonics |
| Biohaven Pharmaceutical Holding Company LTD. | $39.05 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $37.62 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.63 | 2019-2022 | |
| Convatec INC. | $33.24 | 2022-2023 | |
| Amgen INC. | $30.27 | 2024 | Prolia, Evenity |
| Otsuka America Pharmaceutical, INC. | $26.98 | 2025 | Rexulti |
| Lilly USA, LLC | $25.22 | 2022-2023 | Mounjaro |
| Teva Pharmaceuticals USA, INC. | $24.18 | 2022 | |
| Davol INC. | $21.52 | 2021 | |
| Agile Therapeutics, INC. | $20.73 | 2021 | |
| Urovant Sciences INC | $20.07 | 2022 | |
| Merck Sharp & Dohme LLC | $17.55 | 2020 | |
| Medtronic USA, INC. | $16.91 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $16.22 | 2024 | Airsupra |
| Dysis Medical, INC. | $15.63 | 2020 | |
| Acessa Health INC. | $15.49 | 2019 | |
| Minerva Surgical, INC | $15.46 | 2023 | |
| Alnylam Pharmaceuticals INC. | $15.12 | 2021 | |
| Ambu INC. | $13.82 | 2025 | |
| Aspira Women'S Health INC | $12.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robb Rydzynski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.